The scientific literature has demonstrated that probiotics have a broad spectrum of activity, although often the results are contradictory. This study provides a critical overview of the current meta-analyses that have evaluated the efficacy of probiotics in physiologic and pathological conditions, such as metabolic disease, antibiotic-associated and Clostridium difficile-associated diarrhea, IBS, constipation, IBD, chemotherapy-associated diarrhea, respiratory tract infection, ventilator-associated pneumonia, NAFLD, liver encephalopathy, periodontitis, depression, vaginosis, urinary tract infections, pancreatitis, incidence of ventilator-associated pneumonia, hospital infection and stay in ICU, mortality of post-trauma patients, necrotising enterocolitis in premature infants.
Introduction
The scientific literature related to the favorable effects of probiotics on human health has continued to accumulate in recent years, 1 and meta-analyses that have collectively evaluated the effects of probiotics in specific physiologic and pathological conditions are now numerous.
The fields of study in which meta-analysis and systematic reviews have been published concerning the assessment of effectiveness of taking probiotics are given in Table 1 , and cover certain categories of patients (premature infants and trauma patients) and specific diseases, such as metabolic disorders (diabetes, dyslipidemia, hypertension, obesity), gastrointestinal disorders (inflammatory bowel disease, constipation, antibiotic-associated diarrhea, diarrhea secondary to treatment of eradication Clostridium difficile, Helicobacter Pylori, diarrhea secondary to chemotherapy), atopic diseases (atopic syndrome and food hypersensitivity, allergic rhinitis), liver disease (cirrhosis, non-alcoholic fatty liver disease, hepatic encephalopathy), pancreatic disorders (acute pancreatitis), infections of the respiratory tract, urinary tract infections, bacterial vaginosis, periodontitis, and depressive disorder.
The purpose of this study was to perform a review considering all the meta-analysis published in the literature on the effectiveness of the use of probiotics in clinical practice.
Materials and methods
The present systematic review was performed following the steps by Egger et al. 2 as follows: 1. configuration of a working group: 2 operators skilled in clinical nutrition, one skilled in gastroenterology, and one skilled in pediatric, of whom 2 are acting as a methodological operator and 2 participating as clinical operators. 2. Formulation of the revision question on the basis of considerations made in the abstract: "use of probiotics: meta-analysis." 3. Identification of relevant studies: a research strategy was planned, on PubMed [Public MedIine run by the National Center of Biotechnology Information (NCBI) of the National Library of Medicine of Bethesda (USA)], as follows: a) definition of the keywords (probiotics use, meta-analysis), allowing the definition of the interest field of the documents to be searched, grouped in inverted commas ("…") and used separately or in combination; b) use of: the Boolean AND operator, that allows the establishments of logical relations among concepts; c) research modalities: advanced search; d) limits: time limits: papers published in the last 10 years; humans; languages: English; e) manual search performed by the senior researchers experienced in clinical nutrition through the revision of reviews and individual articles on nutrition and body composition published in journals qualified in the Index Medicus. 4 . Analysis and presentation of the outcomes: the data extrapolated from the meta-analysis were collocated in tables; in particular, for each meta-analysis we specified: the author, the name of the journal where the study was published and year of publication, study characteristics and results
5.
The analysis was performed in the form of a narrative review of the reports.
Moreover, since all of the meta-analysis considered in this study included randomized clinical trials, then all studies are with a level of evidence I and II. 3, 4 Results
Metabolic diseases

Diabetes
As for the effectiveness of probiotics in patients with type 2 diabetes, all 5 meta-analysis published to date, 4 involving adult subjects [5] [6] [7] [8] and 1 on both adults and children, 9 shown in Table 2 , agree on a significant reduction in fasting plasma glucose and glycosylated hemoglobin. However, there is no agreement in the demonstration of reduction in blood insulin levels.
The meta-analysis does not specify whether there are more effective strains in blood glucose control, but all stress the need for an intervention that lasts at least 8 weeks to get a significant result. Use as an adjunct to non-surgical periodontal treatment of chronic periodontitis Depression Decrease in the score on the depression scale Children born prematurely Reduction of sepsis, both bacterial and fungal origin, that reduced incidence of severe necrotizing enterocolitis Post-trauma patients Reduction in the incidence of hospital infections, Ventilatory-associated pneumonia and length of intensive care There are statistically significant pooled mean differences between the probiotics and the placebo-controlled groups on the reduction of glucose (¡0¢52 mmol/ l, 95% CI ¡0¢92, ¡0¢11 mmol/l; P D 0¢01) and glycosylated hemoglobin (HbA1c) (¡0¢32%, 95% CI ¡0¢57, ¡0¢07%; P D 0¢01). There was no statistically significant pooled mean difference between the probiotics and the placebo-controlled groups on the reduction of insulin (¡0¢48 mIU/ml, 95% CI ¡1¢34, 0¢38 mIU/ml; P D 0¢27) and HOMA-IR (pooled effect of
¡0¢44,
95% CI ¡1¢57, 0¢70; P D 0¢45). Meta-regression analysis identified that probiotics had significant effects on reduction of glucose, HbA1c, insulin and HOMA-IR in participants with diabetes, but not in participants with other risk factors.
Probiotics may be used as an important dietary supplement in reducing the glucose metabolic factors associated with diabetes 11 studies with 614 subjects in total (continued on next page) 
High-density lipoprotein cholesterol and triglyceride levels did not differ significantly between probiotic and control groups. In subanalysis, long-term (> 4-week) probiotic intervention was statistically more effective in decreasing TC and LDL-C than short-term ( 4-week) intervention. The decreases in TC and LDL-C levels with probiotic intervention were greater in mildly hypercholesterolemic than in normocholesterolemic individuals. Both fermented milk product and probiotic preparations decreased TC and LDL-C levels. Gaio and the Lactobacillus acidophilus strain reduced TC and LDL-C levels to a greater extent than other bacterial strains. L. reuteri NCIMB also markedly reduced TC and LDL-C levels, although it was only included in a single study.
Gaio and the Lactobacillus acidophilus strain reduced TC and LDL-C levels to a greater extent than other bacterial strains.
11 randomized clinical trials with 574 partecipants in total Sun J et al., Ann Med 2015 11 Statistically significant pooled effects of probiotics were found on reduction of total cholesterol, low-density lipoprotein (LDL), body mass index (BMI), waist circumference, and inflammatory markers. Subgroup analysis revealed statistically significant effects of probiotics on total cholesterol and LDL when the medium was fermented milk or yogurt (P < 0.001) compared with capsule form, consumption was at least 8 weeks in duration (P < 0.001), and the probiotics consisted of multiple strains (P 
Dyslipidemia
Concerning the effectiveness of probiotic intake in patients with dyslipidemia, the 4 meta-analyzes published to date, 3 on adults 10-12 and 1 on both adults and children 13 shown in Table 2 , agree affirming that taking probiotics results in a significant reduction in total cholesterol and LDL cholesterol. As for HDL cholesterol, all studies show that intake of probiotics does not determine an increase.
As it regards the probiotic strains evaluated in these 4 meta-analysis, 2 of them 10, 11 that there is a greater efficacy of Lactobacillus Acidophilus than the other species in the reduction of total and LDL cholesterol.
Hypertension
As for the effectiveness of probiotics intake in patients with hypertension, the unique meta-analysis, 14 reported in Table 2 , noted that the intake of probiotics leads to an improvement in systolic and diastolic blood pressure, especially if the baseline blood pressure is 130/85 mmHg, with a treatment duration of at least 8 weeks, with the use of multiple strains and with a daily consumption of 10 11 or more colony forming units.
Obesity
Regarding the effectiveness of probiotics in weight control, the 2 meta-analysis, both published in 2015, presented in Table 2 , show conflicting results: one 15 shows that the intake of probiotics results in a significant reduction of body weight and of the body Mass Index (BMI) reporting that the weight loss is more consistent if the assumption is performed for a time greater than 8 weeks and when taken multiple strains. The other meta-analysis 16 instead shows that there is no efficiency in terms of weight and BMI reduction.
Disorders of the gastro-intestinal tract
Helicobacter pylori
As for the effectiveness of probiotic intake in both adult and pediatric patients, receiving treatment of the eradication of Helicobacter Pylori, 5 [17] [18] [19] [20] [21] of the 6 meta-analysis published to date, shown in Table 3 , [17] [18] [19] [20] [21] [22] agree on a significant improvement of the eradication rate of bacteria when probiotics were used in combination with standard therapy for the eradication. With regard to the side effects of antibiotic therapy used for the eradication, the 5 meta-analysis also show that intake of probiotics helps in the control of these side effects and, in particular, the antibioticassociated diarrhea.
The meta-analysis do not specify whether there are any more effective strains in treatment, although in 2 meta-analysis 17, 20 combinations of probiotics containing Acidophilus and Lactobacilus Bifidobactemium animalis are taken into account, and then the authors conclude that association of these 2 strains is more effective than the single strain.
Inflammatory bowel diseases
With regard to the effectiveness of the probiotics intake in patients having inflammatory bowel diseases (IBD), 2 Cochrane were published, reported in Table 3 : a 2011 Cochrane specific for ulcerative colitis in adult patient 23 and the other Cochrane in 2006 specifically for Crohn's disease in adult and pediatric patients. 24 Both Cochranes agree in reporting that there is insufficient evidence to demonstrate that the administration of probiotics can be helpful in maintaining remission in patients with IBD.
Conversely a more recent meta-analysis published in 2014, 25 presented in Table 3 , however, shows that treatment with probiotics may be an useful therapeutic option for adult and pediatric patients with ulcerative colitis both in combination with specific therapy that in the maintenance phase. For both adult and pediatric patients having Crohn's disease, this metaanalysis confirms the results of the 2 previously mentioned Cochrane analyses, reporting that there is no evidence of effectiveness.
Irritable bowel syndrome
Concerning the effectiveness of probiotics in adult patients with irritable bowel syndrome, the only metaanalysis today published, 26 reported in Table 3 , agrees on the effectiveness of the use of probiotics in reducing the pain and severity of symptoms related, thus demonstrating a beneficial effect of probiotics compared with placebo.
Constipation
As for the effectiveness of probiotics in adult patients with constipation, the only meta-analysis published today, 27 reported in Table 3 , shows that their use may improve intestinal transit, the evacuation frequency and consistency of the faeces, with a subgroup There are adjunctive use of some multi-strain probiotics that may improve H. pylori eradication rates and prevent the development of adverse events and antibiotic-associated diarrhea, but not all mixtures were effective. The use of probiotics plus standard therapy was associated with an increased eradication rate by per-protocol set analysis (RR analyzed would indicate that the beneficial effects of Bifidobacterium Lactis in particular.
Antibiotic-associated diarrhea
Regarding the effectiveness of probiotics in pediatric patients with antibiotic-associated diarrhea, a 2015 Cochrane publication, 28 shown in Table 3 , stressed that their use in pediatric patients may have a pivotal protective role in preventing antibiotic-associated diarrhea. Among the various strains evaluated, in particular Lactobacillus rhamnosus and Saccharomyces boulardii taken in quantity 50 11 of colony forming units/day have proven useful, also given the low probability of the occurrence of adverse events.
Clostridium difficile-associated diarrhea
As for the effectiveness of probiotics in adult patients with diarrhea associated with Clostridium difficile (CDAD), a Cochrane analysis from 2013, 29 presented in table 10, was published, which showed that the use of probiotics represent a safe means and effective for the treatment of this disease, reducing the risk by 64%.
Diarrhea related to chemotherapy
With regard to the effectiveness of probiotics in adult patients with diarrhea associated with chemotherapy performed for the presence of abdominal or pelvic cancer, the only meta-analysis to date published, 30 reported in Table 3 , stressed as their use could have a beneficial effect in the prevention of diarrhea, in particular grade 2 diarrhea, without causing adverse events.
Allergic diseases
Atopic and hypersensitivity syndrome to food in children As for the effectiveness of probiotics in pediatric patients with atopic syndrome and hypersensitivity to food, 3 different meta-analyses, [31] [32] [33] shown in Table 4 , have evaluated the effects of the intake of probiotics in the prevention of atopic syndrome, allergic disease and hypersensitivity related to food in children. According to 2007 Cochrane concerning the prevention of allergic disease and food hypersensitivity, 19 although there was a reduction in infant eczema, these data were not enough to recommend the supplementation of probiotics in infant. The other 2 most recent studies 20, 21 have demonstrated that children treated with probiotics prenatally have lower levels of eczema, with no differences in terms of asthma, wheezing, and rhino-conjunctivitis. Even atopic syndrome and hypersensitivity to food shows a marked improvement in those who are treated with probiotics, as long as the duration of treatment covers the entire prenatal and postnatal periods
Allergic rhinitis
Concerning the effectiveness of probiotics in both adult and pediatric patients with allergic rhinitis, the 2 meta-analyses to date in the literature, shown in Table 4 , have reported conflicting results: the 2015 study 34 has shown that there is not enough evidence to support the concept of the preventive role of probiotics in allergic rhinitis, even if probiotics improve the quality of life and nasal symptoms; conversely, the 2016 meta-analysis by Guvenc 35 which considered 22 double-blind randomized trials, has shown that probiotics, especially L. paracasei, have an important role in the treatment of allergic rhinitis.
Other diseases
Respiratory tract infections
As for the effectiveness of probiotics in patients both adults and children hospitalized in intensive care with ventilator-associated pneumonia, (VAP), the 2014 Cochrane 36 and a meta-analysis 37 presented in Table 5 , are in agreement on the results: to date there is inadequate evidence to recommend probiotics as a routine therapy.
With regard to the effectiveness of probiotics for the prevention and therapy of respiratory tract infections in children, the only meta-analysis to date in the literature 38 has shown that the consumption of probiotics significantly reduces the number of subjects with at least 1 episode of respiratory tract infections; furthermore, children supplemented with probiotics showed the number of days with fever per person and number of days of absence from the nest/school lower than in children who were given a placebo. However, there was no statistically-significant difference in disease duration between the intervention group with probiotics and placebo.
Concerning the effectiveness of the probiotic intake for the prevention and therapy of respiratory tract infections, in children, in adults and in the elderly, the Cochrane analysis published in 2015 39 showed that with regard to prevention or immunologic parameters were noted in the patients with AR. The current evidence is not sufficiently strong to verify a preventive role of probiotics in AR, but probiotics may improve the overall quality of life and nasal symptom scores. Because the available data were generated from only a few trials with a high degree of heterogeneity, routine use of probiotics for prevention and treatment in patients with AR cannot be recommended.
11 randomized, controlled trials of the use of probiotics for the prevention and treatment of allergic rhinitis (n D 1833) Compared with the control arm, the limited evidence suggests that probiotics show a beneficial effect in patients who are having BV. However, the results should be interpreted cautiously because of the heterogeneity among study designs.
12 trials with 1304 patients Huang H, et al. Arch Gynecol Obstet. 2014 44 There was a beneficial outcome of microbiological cure with the oral metronidazole/probiotic regimen (OR 0.09 (95% CI 0.03 to 0.26)) and the probiotic/estriol preparation (OR 0.02, (95% CI 0.00 to 0.47)). For the probiotic/estriol preparation, the OR and 95% CI for physician-reported resolution of symptoms was OR 0.04 (95% CI 0.00 to 0.56). There is no sufficient evidence for or against recommending probiotics for the treatment of BV. The metronidazole/ probiotic regimen and probiotic/estriol perparation appear promising but well-designed randomized controlled trials with standardized methodologies and The use of probiotics decreased the incidence of VAP (odds ratio (OR) 0.70, 95% confidence interval (CI) 0.52 to 0.95, low quality evidence). However, the aggregated results were uncertain for ICU mortality (OR 0.84, 95% CI 0.58 to 1.22 very low quality evidence), in-hospital mortality (OR 0.78, 95% CI 0.54 to 1.14, very low quality evidence), incidence of diarrhea (OR 0. However, the CI of the estimated effect was too wide to exclude no difference with probiotics. There were no reported events of nosocomial probiotic infections in any included study.
Evidence suggests that use of probiotics is associated with a reduction in the incidence of VAP. However, the quality of the evidence is low and the exclusion of the one study that did not provide a robust definition of VAP increased the uncertainty in this finding. The available evidence is not clear regarding a decrease in ICU or hospital mortality with probiotic use. Three trials reported on the incidence of diarrhea and the pooled results indicate no clear evidence of a difference. The results of this meta-analysis do not provide sufficient evidence to draw conclusions on the efficacy and safety of probiotics for the prevention of VAP in ICU patients.
8 randomized controlled trials comparing probiotics with placebo or another control (excluding RCTs that use probiotics in both study groups) to prevent VAP, with 1083 partecipants Probiotics also did not appear to significantly alter any of the other meta-analysis end points.
The limited evidence suggests that probiotics show no beneficial effect in patients who are mechanically ventilated; thus, probiotics should not be recommended for routine clinical application. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs. Future studies should focus on the safety of probiotics. effects of probiotics were minor and gastrointestinal symptoms were the most common. We found that some subgroups had a high level of heterogeneity when we conducted pooled analyses and the evidence level was low or very low quality.
Probiotics were better than placebo in reducing the number of participants experiencing episodes of acute URTI, the mean duration of an episode of acute URTI, antibiotic use and cold-related school absence. However, the quality of the evidence was low or very low. One study reported withdrawal occurred in 6 probiotic participants (5.2%), 15 antibiotic participants (12.2%), while the second study noted one placebo group participant discontinued treatment due to an adverse event. No significant benefit was demonstrated for probiotics compared with placebo or no treatment, but a benefit cannot be ruled out as the data were few, and derived from small studies with poor methodological reporting. There was limited information on harm and mortality with probiotics and no evidence on the impact of probiotics on serious adverse events. Current evidence cannot rule out a reduction or increase in recurrent UTI in women with recurrent UTI who use prophylactic probiotics. There was insufficient evidence from one randomized controlled trial to comment on the effect of probiotics vs. antibiotics. The use of probiotics was associated with a reduction in the incidence of nosocomial infections (5 12 randomized, controlled trials that randomized infants 3 months or younger to oral probiotics vs placebo or no or standard treatment with the outcome of infant crying, measured as the duration or number of episodes of infant crying/distress or diagnosis of "infant colic (1825 infants)
probiotics were better than placebo in reducing the number of people who had episodes of acute infection of the upper respiratory tract, in reducing the average episode length of acute infection of the upper respiratory tract, and in reducing the use of antibiotics and the number of days school/work off.
Liver diseases
As for the effectiveness of probiotics in patients with liver disease, such as non-alcoholic fatty liver disease (NAFLD) and hepatic encephalopathy, today in the literature we find 3 meta-analyses, shown in Table 5 , 2 of which address adult patients with hepatic encephalopathy, and one on patients with NAFLD. The metaanalysis on NAFLD 40 showed that there is a decrease in the levels of liver aminotransferases and an improvement of insulin resistance. Conversely, there are conflicting results in 2 meta-analyses that consider probiotics in patients with hepatic encephalopathy: the 2011 Cochrane study, 41 despite the reduction of plasma ammonia in comparison with placebo, reported no demonstrated effectiveness in improving clinical outcomes, while the other meta-analysis, 42 despite also demonstrating no change in clinical outcomes, reports that probiotics can be helpful in the prevention of the occurrence of overt encephalopathy.
Acute pancreatitis
With regard to the effectiveness of probiotics in patients with acute pancreatitis, the only meta-analysis to date in the literature, 43 reported in Table 2 , have shown no significant effect.
Bacterial vaginosis
As for the effectiveness of probiotics in patients with bacterial vaginosis, the 2 meta-analyses, 44, 45 shown in Table 5 , have not shown sufficient evidence to recommend the use of probiotics for women who suffer from this condition, although the early results are promising.
Urinary tract infections
Concerning the effectiveness of probiotics in adult patients with urinary tract infections, the only metaanalysis published in the literature to date, 46 shown in Table 5 , pointed out that the available data do not allow to establish a valid conclusion.
Periodontitis
As for the effectiveness of probiotics in patients with peridodontitis, the only meta-analysis, 47 reported in Table 5 , assessed the effects of using probiotics as an adjunct to non-surgical periodontal treatment of chronic periodontitis, showed that combination of SRP treatment (scaling and root planing) with the intake of Lactobacillus reuteri may be useful in the short term. However, due to the heterogeneity of the studies and the lack of abundance data available, further investigations are needed to verify than assumed.
Depression
With regard to the effectiveness of probiotics in patients with depression, the only meta-analysis to date in the literature, 48 reported in Table 5 , showed that the intake of probiotics results in an improvement of mood, assessed by a decrease in the score of the scales used to assess the degree of depression in the population under 60.
Patients post-trauma
As for the effectiveness of probiotics in post-trauma patients, both adults and children, the only meta-analysis present in the literature, 49 reported in Table 5 , considered the effectiveness of an early intake of probiotics, through enteral nutrition, on clinical outcomes, such as incidence of hospital infections, ventilator-associated pneumonia, the hospital stay in ICU and mortality. The meta-analyses showed that probiotics are a valuable aid to reduce the incidence of hospital infections, ventilator-associated pneumonia and hospitalization time in intensive care, but treatment with probiotics is not associated with reduce of mortality.
Premature birth
As for the effectiveness of probiotics in born pre-term patients, 2 meta-analysis, 50, 51 shown in Table 5 , which evaluated the correlation between probiotic supplementation (per os or enterally) and late-onset sepsis, bring into evidence that treatment with probiotics is capable of reducing the disease of bacterial and fungal origin, even if there are no indications about the type of probiotic used in the studies. Another meta-analysis of 2013, 52 which analyzed the presence of the "infant colic crying" with the supplementation of probiotics, in particular Lactobacillus Reuteri, showed that there is still insufficient evidence to support probiotic use to manage colic or to prevent infant crying.
Concerning the necrotising enterocolitis in premature infants, the 2014 Cochorane study shows that supplementation with Lactobacillus or with the combination of Lactobacillus and Bifidobacterium reduces the incidence of this serious disease. 53 
Discussion
As regards the metabolic diseases (diabetes, dyslipidemia, obesity and hypertension), the meta-analysis showed that to demonstrate the efficacy of probiotics in favourably modifying the specific major metabolic outcomes (total cholesterol, LDL cholesterol, blood glucose, decreased body weight, decreased blood pressure), further well-conducted studies are required. Concerning the probiotic strains, 2 meta-analyses 10, 11 agree that there is a greater efficacy of Lactobacillus Acidophilus than the other species in the reduction of total and LDL cholesterol.
As for the effectiveness of probiotic intake in both adult and pediatric patients, receiving treatment of the eradication of 'Helicobacter Pylori, 5 [17] [18] [19] [20] [21] of the 6 meta-analyses published to date, agree on a significant improvement of the eradication rate of bacteria when probiotics were used in combination with standard therapy for the eradication. The meta-analysis do not specify whether there are any more effective strains in treatment, although in 2 meta-analysis 17, 20 are taken into account combinations of probiotics containing Acidophilus and Lactobacilus Bifidobactemium animalis, and then the authors conclude that association of these 2 strains is more effective than the single strain.
Either in case of antibiotic-associated diarrhea (in adults and children) or in case of diarrhea associated to Clostridium difficile (in adults and elderly), the efficacy of probiotics was considered evidence based.
Regarding the effectiveness of probiotics in patients with antibiotic-associated diarrhea, among the various strains evaluated, in particular Lactobacillus rhamnosus and Saccharomyces boulardii taken in quantity 50 11 of colony-forming units/day, have proven useful by the 2015-published Cochrane analysis, 28 also given the low probability of the occurrence of adverse events.
Concerning Clostridium difficile-associated diarrhea (CDAD), Cochrane Database 2013 29 demonstrated that probiotics are both safe and effective for preventing CDAD; in particular, the results of this Cochrane study suggest that when probiotics are given with antibiotics, they reduce the risk of developing CDAD by 64%. Although probiotics are clearly superior to placebo or no treatment of preventing CDAD, further head-tohead trials are warranted to distinguish optimal strains and dosages: in fact, covariates of clinical interest such as strain and dose need to be evaluated further. The authors began with the hypothesis that the mechanism of action of various probiotics was similar and that any variation in effect would be due to chance.
As for the effectiveness of probiotics in adult patients with constipation, the only meta-analysis published today 27 shows that their use may improve intestinal transit, the evacuation frequency and consistency of the faeces, with a subgroup analyzed would indicate that the beneficial effects of Bifidobacterium Lactis in particular.
For irritable bowel syndrome, chemotherapy-associated diarrhea and IBD, the efficacy has yet to be demonstrated, though recently a meta-analysis by Fujiya 25 demonstrated that probiotic treatment is a practical option for ulcerative colitis patients as both remission induction and maintenance therapy, but such treatment is not effective in Crohn Disease patients.
In case of respiratory tract infection, the efficacy of probiotics (in adults and children) to reduce the number of infection episodes and the number of days of absence from school/work was considered evidencebased: the Cochrane study published in 2015 39 showed that probiotics were better than placebo in reducing both the number of people who have had episodes of acute infection of the upper respiratory tract, in reducing the average length of an episode of acute infection of the upper respiratory tract, and in reducing the use of antibiotics and the number of days school/work off. Although probiotics are clearly superior to placebo or no treatment of preventing respiratory tract infection, further trials are warranted to distinguish optimal strains and dosages, therefore the Cochrane study did not identify the types of strains and the dosages of administration.
Concerning allergic rhinitis (AR), despite high variability among the studies and therefore the need for further studies, synthesis of available data provided significant evidence of beneficial clinical and immunologic effects of probiotics in the treatment of AR, especially with seasonal AR and in particular with Lactobacillus paracasei-33 strains, as demonstrated by 2016 meta-analysis by Guvenc. 35 Regarding ventilator-associated pneumonia in adults and children admitted to ICU, the efficacy of probiotics to modify the major clinical outcomes and mortality needs further well-conducted studies.
Considering liver diseases, vaginosis, urinary tract infections, periodontitis, depression and pancreatitis, the efficacy of probiotics has yet to be demonstrated with well-conducted studies. As for the effectiveness of probiotics in patients with peridodontitis, the only meta-analysis 47 assessed the effects of using probiotics as an adjunct to non-surgical periodontal treatment of chronic periodontitis, and showed that combination of SRP treatment (scaling and root planing) with the intake of Lactobacillus reuteri may be useful in the short term. However, due to the heterogeneity of the studies and the lack of abundance data available, further investigations are needed.
Concerning the necrotising enterocolitis in premature infants, the 2014 Cochorane study shows that supplementation with Lactobacillus or with the combination of Lactobacillus and Bifidobacterium reduces the incidence of this serious disease. 53 In conclusion, some effects of probiotics are well documented, and their use alone or in combination with other therapies can therefore be considered "evidence-based," such as for antibiotic-associated diarrhea (in adults and children), and Clostridium difficile-associated diarrhea (in adults and elderly). In other clinical conditions, however, further studies are needed, because the available evidence is insufficient to show the efficacy of probiotics themselves. Carefully designed clinical trials are needed to validate the effects of particular strains of probiotics given at specific dosages and for specific treatment durations.
